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? separate group for cluster analysis ?growing evidence of risk factors DPPs Validated within groups from within original data Major suggestions Pg 10 ln 214 -How did the results vary with and without the outliers. It is possible to have a patient with many risk factors but being treated appropriately with medications, so I'm not sure appropriate to exclude these patients. Excluding them will improve your risk assessment but these are true patients in our hospitals. You could present results somewhat like an intent to treat with keeping all patients in, and then analyzing with excluded "outliers." With both sets of data, the reader can then make their own adjustment about the tool and appropriateness of excluding the perceived "outliers." Pg 8 Ln 164 -The correlation cut points seems a bit low for clinical decision-making; but the tool is for screening. Since these seem low to me, best to put these definitions into the abstract for them to know what is a strong association. Pg 11 Ln 224-226 and methods section -I am not clear why cluster analysis versus dividing patients by number of risk factors as low (e.g. 1-8), intermediate (e.g. 9-16), high (e.g. 17-23). Both cluster analyses have overlap in terms of risk factors. Or dividing patients by MAI scores and assessing DART scores. Giving more predictability data by subgroups of DART would be useful information. The cluster analysis then is for helping with identifying the key independent items to limit survey burden. Pg 14 ln 280 -Can the 5 item DART select people for a patient interview? Or are you still doing an interview on all to find the single discriminatory items?
Additional Specific Suggestions Pg 1 Ln 11 -Add pharmacist, add older adult/aged, add polypharmacy Pg 2 Ln 27 -Add already receiving pharmacy services Pg 2 ln 33 -End sentence after items. And add -We determined which DART and patient interview questions to trigger a formal pharmacist medication review. Pg 2 Ln 36 -The results are confusing since this is an analysis of the two cluster groups created versus ability of the tool in either high or low risk factors or high or low potential and manifest DRPs. Pg 2 ln 38 -Add the correlations for moderate and strong relationships. Pg 2 Ln 41 -Isn't the conclusion limited DART plus patient interview were able to allocate pharmacy resources. Pg 3 ln 50 -Is this for older adults or all age groups. Do only older adults get on your geriatric wards? Pg 3 Ln 52 -Does anything need to be added about accuracy of self-reported DART items? Pg 4 ln 59 -DRPs can result from good prescribing as well since we can't always predict pt response; good to include patient behaviors; also can be related to family and caregivers Pg 5 ln 82 -Give a couple more lines about the tool since it is the main outcome measure. Was reference 12 a creation study, validation and reliability study, other study type? Where the 35 items pulled from evidence based risk factors for DRPs? Can you briefly describe what data were triangulated? Did you evaluate the first creation study sample by age group? Did you analyze separately potential and manifest DRPs? Would be interesting to see how tool performance changed for the different groups, with the manifest being more important than potential. Pg 5 Ln 89 -Is part of the goal to see how it performs in an older adult population also? I suspect the first tool development study was in all hospitalized patients; is that true? Pg 7 Ln 149 -Is the clinical dimension for harm, benefit, or harm and benefit. Pg 7 Ln 150 -Definition not clear to me. Prohibit potential damage from disease?; requires additional treatment because the medication is not working? Surveillance seems to be a third dimension related to appropriate monitoring in your definition. Pg 9 Ln 195 -Data are in the table so they don't need to be listed in text. Pg 9 Ln 198 -Add a footnote to describe definition of medication. Does it include herbal agents, supplements, and as needed medications? Pg 9 ln 200 -Please state the number of potential DRPs and manifest DRPS. Pg 9 Ln 204 -Acetaminophen problem dose too high? Pg 10 table 2 -Please add columns to separate data into potential, manifest, and total. Pg 10 Ln 17 -Can you describe more what insufficient knowledge of patient is and how it relates to a DRP? Add as a footnote Pg 10 Ln 18 -Can you describe more what incomplete patient documentation is and how it relates to a DRP? Add as a footnote Pg 11 ln 273 and 275 -Add the correlation numbers after weak, moderate and strong. Some people don't read the methods so it is good for them to know your definitions.
VERSION 1 -AUTHOR RESPONSE

Answers to Reviewers' Comments
The authors would like to send their gratitude to the reviewers for their constructive feedback. The comments improved the article and allowed a critical review of the performed research.
Reviewer 1 Comment Answer
There is need to improve the title to become more Giving more predictability data by subgroups of an artificial cut-off for a tolerable number of DRPs DART would be useful information. The cluster (e.g. low risk patients having four DRPs), a cluster analysis then is for helping with identifying the key analysis was used. Cluster analyses group independent items to limit survey burden. observations into collectives with respect to all defined variables without necessitating previous categorisation and without subjective human bias.
In his comment, the reviewer used an artificial subgroup division of the patients into low, intermediate, and high, actually requiring further explanations or a citation. We circumvented this by applying a cluster analysis, grouping the data as We determined which DART and patient interview However, the patient interview was part of the questions to trigger a formal pharmacist medication medication review, not part of the DART. Changed review. the wording accordingly to "We determined which DART items may be used to trigger a clinical medication review including a patient interview."
Pg 2 Ln 36 -The results are confusing since this is Thank you, we changed the wording to be clearer.
an analysis of the two cluster groups created versus ability of the tool in either high or low risk factors or high or low potential and manifest DRPs.
Pg 2 ln 38 -Add the correlations for moderate and We now included the Spearman's rank correlation strong relationships.
coefficient as stated number into the results section of the abstract.
Pg 2 Ln 41 -Isn't the conclusion limited DART plus The patient interviews were part of the criterion patient interview were able to allocate pharmacy measure, not part of the measure being resources. investigated, hence we kindly ask to be allowed to leave our wording as is. 
GENERAL COMMENTS
Thank you for your consideration of comments, reflection and revision of the manuscript. This study contributes to the expanding evidence-base supporting the prioritisation of patients by vulnerability to drug related problems and the allocation of scarce medication management resources. The authors justify the benefits of a self-administered questionnaire which supports prioritisation independent of clinical data.
There are a number of remaining issues for consideration: Generalisability: The authors have responded to comments from reviewers 2 and 3. However, overall the population of patients for whom DART is generalisable remains ambiguous and will benefit from clarification. It seems that DART is validated for patients admitted to geriatric and rehabilitation wards (The "ward" type, and not the patient characteristics is reported, however, it remains unclear for readers who would like to appraise the relevance of DART whether the unit of analysis is the ward, or a particular patient characteristic (i.e. age or acuity or experiencing rehabilitation (not defined). I expect the former, but this is ambiguous because patient cohorting, in particular to rehabilitation services, is not well defined in this paper, and likely varies across countries and settings. Patient acuity: In the authors' response to reviewers, it is reported that patient acuity was not recorded or assessed, and that all patients were "stationary" (please define). Suggest this needs to be included and elaborated upon in the manuscript. This has important implications regarding generalisability to acute hospital settings. Equally, although the abstract states that participants included 110 of 437 patients, and figure 1 outlines the study flow, there remains opportunity to clarify in the stated study limitations that DART is generalisable only to patients who were able to engage in conversation. Reviewer 3 raises the issue of the use of an intent to treat type analysis, and I agree with the need for this, and that the authors still need to address this issue. Although the authors justify that such analysis would not align with their chosen analysis method , the authors' response does not address the actual appropriateness of their chosen analysis method. Linked to this is the authors' rationale for SQUIRE. The authors have presented a potential future QI application SQUIRE, which is fine. However, the more pertinent issue is the absence of a reporting guideline relevant to either observational studies or prediction studies. "Rehabilitation": The rehabilitation units or patient cohort is not clearly defined for the reader. There is a need for consistency through the manuscript, which in the majority of instances throughout mentions the "geriatric" cohort only. Ultimately, I consider that there is room to be more transparent about the population group for whom DART might be useful. It seems that this is for older non-acute medical patients with the ability to engage in conversation, and that it allows for prioritisation within this cohort. However, it does not seem to enable or support prioritisation of medication review intensity outwith that and there is room for clarification of this. 
GENERAL COMMENTS BMJ DART
The authors have addressed all the reviewer comments either in the text or reviewer feedback. The changes to the text strengthened the paper so that the reader understands better the science, esp. since most readers don't have the time to pull the previous articles with the tool. The study sample is more clearly described. Authors provided increased information to justify eliminating the outliers. The additional information about the statistics and tools is helpful. Additional results provide useful information. The findings then allow a short form, augmented MRT3 trigger form, and full DART assessment tool.
Just a few minor comments.
Pg 1 ln 2 add hospitalized before patient in title Pg 2 ln 19 add hospitalized before patient in abstract Pg 2 ln 36 add pharmacist before clinical medication review Pg 3 ln 45 to stratify patients in low and high likelihood of having DRPs groups.
Pg 3 ln 46-47. Is this the result? The analysis showed that a short form of DART, i.e. 5 items, can be used instead of the full 35 item tool to identify patients at risk for DRPs. An additional 8 items from the DART can also be used to trigger additional needs for clinical pharmacy services. Thus both the short, augmented short form, and full DART tool enable pharmacist resource allocation. This will increase word count, which I suspect might be approved. Pg 17-18 a limitation still needs to address the 5 outliers; something related to tool did not perform well for all patients.
Pg 18 Ln 362 Did you mean healthcare providers vs the caregivers? We generally assume caregivers as family and friends, not healthcare providers.
VERSION 2 -AUTHOR RESPONSE Answers to Reviewers' Comments
The authors would like to send their gratitude to the reviewers for their second constructive feedback. The comments further improved the clarity of the article and allowed for a critical review of the performed research.
To ease the correspondence, we copied all comments into a table, which is sorted by reviewers. The reviewers' comments are on the left side; the authors' answers are on the right side. We applied the following colour scheme to our answers: Green states implementation, yellow states implementation which may be regarded as only partial, and orange states currently no implementation into the main body/only further clarification. outcomes, it has to be followed by appropriate interventions. The DART, however, may help to direct interventions to patients in need of optimising pharmacotherapy and by this improve clinical outcomes."
We disseminated these limitations throughout the manuscript and by adding "older non-acute patients" to Implications for practice and rewriting our conclusions to: "We present the DART as a validated selfadministered questionnaire that may be used to identify a high risk of DRPs in hospitalised older non-acute patients able to engage in a conversation. Subsets of the items may trigger different clinical pharmacy services for patients in need and allow for rational allocation of work resources."
We do hope that we were able to address the issue on patient acuity with the changes listed above. We would like to thank the reviewer for providing us with the phrasing: "older non-acute patients with the ability to engage in conversation"
Reviewer 3 raises the issue of the use of an intent We agree with the reviewers on the benefits of an intention-to-treat to treat type analysis, and I agree with the need for analysis. However, the use of a Ward's hierarchical cluster analysis this, and that the authors still need to address this clearly necessitates the exclusion of statistical outliers and unfortunately issue. Although the authors justify that such prohibits us from conducting an intention-to-treat analysis with the whole analysis would not align with their chosen analysis dataset. To address the concerns by the reviewers, which will hence method , the authors' response does not address persist, we decided on three points of improvement to our manuscript:
the actual appropriateness of their chosen analysis
(1) We re-phrased the section on the statistical analysis in order to method.
formulate the analysis and the decision for using a cluster analysis more approachable for the readers, (2) we transparently describe the five outliers in the results section, and (3) we discuss the excluded outliers in the limitations section of the manuscript.
Comment for the author Answer to the reviewer These texts now read:
1. "The total DART risk-score was calculated by assigning points to each answer. Dichotomous answers were assigned a risk-score with one (1) point being assigned to each 'Yes' answer and zero (0) points given to each 'No' answer. Ordinal answers were assigned a corresponding dummy variable. As studies reported means of eight to ten identified DRPs per patient,31 32 the dependent variable (i.e. numbers of DRPs) was expected to lack a predefined cut-off value, i.e. low risk patients having zero DRPs. Instead of defining an artificial cut-off for a tolerable number of DRPs (e.g. low risk patients having four DRPs), we used a cluster analysis. Cluster analyses group observations into collectives with respect to all defined variables (i.e. DART score, number of DRPs) without necessitating previous categorisation: the analysis was expected to form patient clusters with high DART scores and high numbers of DRPs and low DART scores and low numbers of DRPs in the absence of an artificial definition of high and low. We performed a Ward's hierarchical cluster analysis with squared Euclidian distance using the variables DART score and number of DRPs. This analysis necessitated the elimination of statistical outliers in order to be performed. For this reason, Backhaus and colleagues recommend a preceding single linkage hierarchical cluster analysis with squared Euclidian distance. Statistical outliers can be objectively identified from the resulting dendrogram.33 We assessed the appropriateness of the clusters generated by the Ward's hierarchical cluster analysis by homogeneity and calculated the F-values for each cluster and variable (i.e. DART total risk-score and number of DRPs). F-values of below 1 represent a homogeneity that is lower within the proposed cluster than within all observations.33 We performed effect size calculations using Pearson's correlation coefficient r, which were interpreted according to Gignac: r=.1 as small, .2 as medium, and .3 as large.34 We compared the obtained clusters concerning their total number of identified DRPs and their total DART risk-score by a Mann-Whitney UTest.35 Furthermore, we performed a step-wise discriminant function analysis in order to investigate the discriminatory potential of subsets of items of the questionnaire for the generated clusters and hence to identify possibilities to reduce the number of items in the questionnaire. We calculated Wilks' Lambda (λ) for the whole DART questionnaire and the subsets of items ('reduced items') to report on discriminatory values. Lower Wilk's λ values indicate a higher differential potential.33 For scale correlations, we used Spearman's rank correlation coefficient ρ, which we interpreted as follows: ρ =.1 as weak,
.3 as moderate, and .5 as strong.36 An Area Under the Receiver Operating Characteristic curve (AUROC) analysis for the reduced items was performed. As described above, cluster analysis and subsequent discriminant factor analysis were again used to additionally determine discriminatory DART items concerning DRPs identified within the patient interviews only. Additionally, we calculated Spearman's rank correlation coefficient ρ to assess the correlation between the score of the reduced items and the potential relevance of the detected DRPs. For the single items, we used a Mann-Whitney U-Test. These additional tests were used to assign the necessary extent of medication reviews to certain items of the DART. clinical/patient, economic/hospital, and organisational/staff. For our research we focused on the clinical dimension, with its six levels 'harmful', 'null', 'minor', 'moderate', 'major', and 'lifesaving', which achieved good interrater (intra-class correlation ICCA, 1 = .63) and excellent test-retest reliability (mean I̅ C ̅ C ̅ A, 1 = .76)."
Pg 17-18 a limitation still needs to address the 5
In accordance to concerns raised by reviewer 2 we rephrased the outliers; something related to tool did not perform methods section on the statistical analysis to be more approachable in well for all patients.
regards to why we performed certain steps. Additionally, we now more specifically describe the five outliers in the results section. The specific request the reviewer posed here was addressed by adding the following phrases to our limitations section: 
GENERAL COMMENTS
Thanks to the authors for continuing to add clarification and detail to emphasize the importance of their tool to assist with workforce management and improving patient care
